NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $15.54 +0.88 (+6.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$15.54 0.00 (-0.03%) As of 07/2/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Janux Therapeutics Stock (NASDAQ:JANX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Janux Therapeutics alerts:Sign Up Key Stats Today's Range$14.64▼$15.5950-Day Range$13.15▼$15.5452-Week Range$12.12▼$35.34Volume1.04 million shsAverage Volume1.36 million shsMarket Capitalization$947.63 millionP/E RatioN/ADividend YieldN/APrice Target$40.15Consensus RatingModerate Buy Company Overview Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors. Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients. AI Generated. May Contain Errors. Read More Janux Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreJANX MarketRank™: Janux Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 218th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 10 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialJanux Therapeutics has a consensus price target of $40.15, representing about 158.4% upside from its current price of $15.54.Amount of Analyst CoverageJanux Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.70) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.56% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 10.96, which indicates bearish sentiment.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 5.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentJanux Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Janux Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows9 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $85,826.00 in company stock.Percentage Held by Insiders7.90% of the stock of Janux Therapeutics is held by insiders.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JANX Stock News HeadlinesJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 1 at 2:16 AM | americanbankingnews.comIs Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?June 30 at 9:46 AM | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 3 at 1:00 AM | Banyan Hill Publishing (Ad)Janux Therapeutics Inc Ordinary Shares JANXJune 28, 2026 | morningstar.comM5 Most Promising Cancer Stocks According to Wall Street AnalystsJune 28, 2026 | insidermonkey.comJanux Therapeutics Announces Departure of Chief Medical OfficerJune 23, 2026 | tipranks.comJanux Therapeutics Reports Results of 2026 Annual MeetingJune 12, 2026 | tipranks.comJanux Therapeutics (NASDAQ:JANX) Insider Janeen Noel Doyle Sells 4,059 SharesJune 5, 2026 | insidertrades.comSee More Headlines JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $13.80 at the beginning of the year. Since then, JANX shares have increased by 12.6% and is now trading at $15.54. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million for the quarter, compared to analysts' expectations of $4.36 million. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $182 million in an initial public offering (IPO) on Thursday, June 10th 2021. The company issued 11,400,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional shareholders of Janux Therapeutics include Versant Capital Management Inc. Insiders that own company stock include Ra Capital Management, LP, Tighe Reardon, Jay Lichter, David Alan Campbell, Thomas Diraimondo, Andrew Hollman Meyer, Charles M Winter, Janeen Noel Doyle, Maria Dobek, Zachariah Mciver and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Janux Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AUO (AUOTY). Company Calendar Last Earnings5/07/2026Today7/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 JANX's financial health is in the Red zone, according to TradeSmith. JANX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Janux Therapeutics$40.15 High Price Target$100.00 Low Price Target$14.00 Potential Upside/Downside+158.4%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.62 million Net MarginsN/A Pretax Margin-833.60% Return on Equity-12.93% Return on Assets-12.23% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$10 million Price / Sales94.76 Cash FlowN/A Price / Cash FlowN/A Book Value$15.91 per share Price / Book0.98Miscellaneous Outstanding Shares60,980,000Free Float56,166,000Market Cap$947.63 million OptionableOptionable Beta2.52 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:JANX) was last updated on 7/3/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
